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These results were presented at the European Society of Cardiology‐Acute Cardiovascular Care Association (ESC‐ACCA) Conference, March 3 to 5, 2018, in Milan, Italy.

Clinical PerspectiveWhat Is New?In a multicenter study of young patients (aged 18--55 years) diagnosed with acute myocardial infarction, we found myocardial infarction with nonobstructive coronary arteries (MINOCA) to be prevalent in 11%, predominantly among women and nonwhite patients.Patients with MINOCA were less likely to have traditional cardiac risk factors and more likely to have hypercoaguable states than those with myocardial infarction due to coronary artery disease.When tested for the underlying mechanism, MINOCA patients had variable causes such as coronary artery vasospasm, spontaneous coronary artery dissection, or coronary artery embolization. The clinical profile, management, and prognosis of these patients also varied based on the cause, necessitating further workup.What Are the Clinical Implications?In young patients with acute myocardial infarction, the course of MINOCA was not benign; 1‐ and 12‐month mortality and functional and psychosocial outcomes were similar to those of patients with myocardial infarction due to coronary artery disease.Patients with acute myocardial infarction who are ruled out for obstructive coronary artery disease should undergo additional testing to elucidate the underlying cause of ischemia and to initiate appropriate treatment.

Introduction {#jah33226-sec-0009}
============

Patients with myocardial infarction with nonobstructive coronary arteries (MINOCA) constitute 6% to 14% of all those with acute myocardial infarction (AMI).[1](#jah33226-bib-0001){ref-type="ref"}, [2](#jah33226-bib-0002){ref-type="ref"}, [3](#jah33226-bib-0003){ref-type="ref"}, [4](#jah33226-bib-0004){ref-type="ref"}, [5](#jah33226-bib-0005){ref-type="ref"}, [6](#jah33226-bib-0006){ref-type="ref"}, [7](#jah33226-bib-0007){ref-type="ref"}, [8](#jah33226-bib-0008){ref-type="ref"} Recent evidence demonstrates that patients with MINOCA are distinct from patients with AMI with the classic culprit lesion---namely, \>50% plaque‐mediated occlusion of the coronary artery (myocardial infarction due to coronary artery disease \[MI‐CAD\])---by having lower prevalence of the traditional cardiac risk factors and a lower but clinically significant annual mortality rate.[1](#jah33226-bib-0001){ref-type="ref"}, [5](#jah33226-bib-0005){ref-type="ref"}, [6](#jah33226-bib-0006){ref-type="ref"} Seen more commonly in women and young patients, existing literature on MINOCA is extrapolated from studies enrolling predominantly men and older patients, and this may limit opportunities to fully describe the different phenotypes of disease defined as MINOCA, their clinical profiles, and their associated outcomes.[3](#jah33226-bib-0003){ref-type="ref"}, [6](#jah33226-bib-0006){ref-type="ref"}, [9](#jah33226-bib-0009){ref-type="ref"}, [10](#jah33226-bib-0010){ref-type="ref"}, [11](#jah33226-bib-0011){ref-type="ref"}

Current knowledge regarding outcomes of MINOCA patients has been limited primarily to mortality. Little is known about the clinical profile of specific phenotypes or the functional, psychosocial, and health status of these patients.[6](#jah33226-bib-0006){ref-type="ref"} Confusion also exists regarding the definition of MINOCA.[12](#jah33226-bib-0012){ref-type="ref"} In contemporary literature, MINOCA is an umbrella term for all causes of troponin elevation inclusive of coronary causes of ischemia (eg, plaque rupture, spasm, spontaneous coronary artery dissection \[SCAD\], or embolization) and noncoronary causes (eg, myocarditis or takotsubo).[13](#jah33226-bib-0013){ref-type="ref"} More recently, however, it has been proposed to primarily describe patients with coronary‐related ischemia.[12](#jah33226-bib-0012){ref-type="ref"} The dual interpretation is reflected in the heterogeneity of the inclusion criteria of earlier studies and has resulted in disparities in describing the clinical profile, course, and prognosis of these patients.[5](#jah33226-bib-0005){ref-type="ref"}, [6](#jah33226-bib-0006){ref-type="ref"}, [14](#jah33226-bib-0014){ref-type="ref"}, [15](#jah33226-bib-0015){ref-type="ref"}

Young women with AMI represent an ideal population in which to clarify MINOCA‐related questions. In this population, nonobstructive disease is common, yet outcomes including mortality are worse compared with men.[16](#jah33226-bib-0016){ref-type="ref"} The VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients) study, the largest prospective multicenter study that enrolled young adults under age 55 years with a diagnosis of AMI and had an oversampling of women,[17](#jah33226-bib-0017){ref-type="ref"} provides an ideal opportunity to look more carefully at MINOCA. One in 8 young women in VIRGO had no evidence of plaque rupture or thrombosis, allowing pathophysiologically driven insight into the study of ischemic MINOCA.[18](#jah33226-bib-0018){ref-type="ref"} Accordingly, we studied this sample to better characterize the presentation, sociodemographic and psychosocial data, clinical characteristics, sex‐specific factors (eg, perimenopausal and peripartum status), and outcomes in MINOCA versus MI‐CAD patients and among MINOCA patients by phenotypic mechanism and sex.

Methods {#jah33226-sec-0010}
=======

Setting and Participants {#jah33226-sec-0011}
------------------------

We analyzed the US VIRGO registry, with a study population of 2985 patients (2009 women, 976 men). The VIRGO investigators intend to share study data and are investigating mechanisms and funding to make that possible. We are currently working on 2 pilot data‐sharing efforts. VIRGO was a prospective observational study of patients aged 18 to 55 years presenting with an AMI in 103 geographically diverse hospitals from August 2008 to January 2012 using a strict 2:1 enrollment ratio of women to men. AMI was defined as (1) an increase in cardiac biomarkers (troponin I or T or creatine kinase‐MB) with at least 1 value \>99th percentile of the upper reference limit within 24 hours of admission and (2) supporting evidence of acute myocardial ischemia, including symptoms or ECG changes.[18](#jah33226-bib-0018){ref-type="ref"} Patients with elevated cardiac markers due to a complication of elective coronary revascularization, presumed myocarditis, or takotsubo were not eligible for VIRGO. Only patients who underwent cardiac catheterization were included in our analysis. Patients who received thrombolytics before undergoing angiography were excluded. Institutional review board approval was obtained at each participating center, and all patients provided written informed consent to participate.

Patient Characteristics and Outcomes {#jah33226-sec-0012}
------------------------------------

Information was obtained by medical chart abstraction, and standardized in‐person interviews were performed by trained personnel during the index admission for the following variables. Self‐identified race was categorized as *black, white*, or *other*, and ethnicity as hispanic or non‐hispanic. Chest pain symptoms were defined as pain, pressure, tightness, or discomfort in the chest. For women, reproductive and menstrual history was obtained. Information on cardiac risk factors and cardiac procedures as listed in Table [1](#jah33226-tbl-0001){ref-type="table"}, hypercoaguable syndromes (as charted by the treatment team), clinical severity of AMI (peak troponin level, ejection fraction \<40%), in‐hospital therapies received (revascularization, automatic implantable cardioverter‐defibrillator insertion), discharge medications, length of stay, disposition and final adjudicated ECG diagnosis (ST‐segment--elevation myocardial infarction \[STEMI\] versus non‐STEMI) were also collected. Validated standardized instruments were used to assess psychosocial and health status. These included (1) depression using the 9‐item Patient Health Questionnaire (PHQ‐9), with higher scores indicating increasing severity (range 0--27)[19](#jah33226-bib-0019){ref-type="ref"}, [20](#jah33226-bib-0020){ref-type="ref"}, [21](#jah33226-bib-0021){ref-type="ref"}, [22](#jah33226-bib-0022){ref-type="ref"}; (2) perceived stress using the 14‐item Perceived Stress Scale (PSS), with higher scores indicating higher stress levels (range 0--40)[23](#jah33226-bib-0023){ref-type="ref"}, [24](#jah33226-bib-0024){ref-type="ref"}; and (3) health status outcomes (patients' physical limitations, angina frequency, and quality of life related to angina) using the Seattle Angina Questionnaire (SAQ; scores ranging from 0 to 100), with higher scores indicating better health status.[25](#jah33226-bib-0025){ref-type="ref"}, [26](#jah33226-bib-0026){ref-type="ref"}, [27](#jah33226-bib-0027){ref-type="ref"}, [28](#jah33226-bib-0028){ref-type="ref"}, [29](#jah33226-bib-0029){ref-type="ref"} In addition, detailed review of medical charts was conducted to better characterize the AMI phenotypes.

###### 

Risk Factor Profile and Clinical Characteristics in Patients With MI‐CAD and MINOCA

                                                  MI‐CAD n=2374 (88.8%)   MINOCA n=299 (11.2%)   *P* Value
  ----------------------------------------------- ----------------------- ---------------------- ------------------------------------------------
  Demographics                                                                                   
  Age, y, median (IQR)                            48 (44--52)             46 (40--51)            \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Women                                           1541 (64.9)             269 (90.0)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  White                                           1824 (76.8)             203 (67.9)             0.008[b](#jah33226-note-0005){ref-type="fn"}
  Hispanic origin                                 169 (7.1)               31 (10.4)              0.022[c](#jah33226-note-0006){ref-type="fn"}
  Risk factors---conventional                                                                    
  Hypertension                                    1595 (67.2)             164 (54.9)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Diabetes mellitus                               750 (31.6)              52 (17.4)              \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Dyslipidemia                                    1653 (69.6)             164 (54.9)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Smoking in past 30 d                            1430 (60.3)             103 (34.5)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Obesity                                         1285 (54.1)             126 (42.1)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Family history of CAD                           1785 (75.2)             184 (61.5)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Any of above risk factors                       2342 (98.7)             273 (91.3)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Stroke/TIA                                      112 (4.7)               9 (3.0)                0.19
  Prior AMI                                       517 (21.8)              37 (12.4)              \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  CHF                                             107 (4.5)               13 (4.4)               0.93
  Prior PAD                                       63 (2.7)                0 (0)                  0.004[b](#jah33226-note-0005){ref-type="fn"}
  Risk factors---unconventional                                                                  
  Depression                                      788 (34.6)              83 (28.6)              0.06
  Perceived stress, median (IQR)                  26.0 (19.0--32.0)       26.0 (19.0--32.0)      0.65
  History of cocaine use                          110 (4.6)               18 (6.0)               0.28
  History of illicit drug use (not cocaine)       192 (8.1)               31 (10.4)              0.16
  AMI triggered by cocaine use                    29 (1.2)                4 (1.3)                0.78
  Hypercoagulability syndrome                     31 (1.3)                9 (3.0)                0.036
  Venous thromboembolism                          62 (2.6)                11 (3.7)               0.27
  Autoimmune disease                              70 (2.6)                12 (4.0)               0.29
  Known renal dysfunction                         261 (11.0)              27 (9.1)               0.32
  Thyroid disorders                               159 (6.7)               29 (9.7)               0.05
  For women only (n=1808)                                                                        
  Polycystic ovarian disease                      11 (0.7)                2 (0.7)                0.95
  Menopause                                       850 (55.2)              110 (40.9)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Age at menarche, median (IQR)                   12.0 (11.0--13.0)       13.0 (12.0--14.0)      0.003[b](#jah33226-note-0005){ref-type="fn"}
  OCP use (n=1395)                                39 (3.3)                7 (3.4)                0.90
  Ever got pregnant                               1361 (88.4)             232 (86.2)             0.49
  For women who have been pregnant (n=1592)                                                      
  Preeclampsia                                    360 (26.7)              67 (29.1)              0.43
  Gestational diabetes mellitus                   224 (16.8)              25 (10.9)              0.028[c](#jah33226-note-0006){ref-type="fn"}
  Stillbirth                                      68 (05.0)               12 (5.2)               0.91
  Miscarriage                                     391 (29.0)              65 (28.1)              0.82
  Diagnosis                                                                                      
  Prehospital ECG                                 639 (27.1)              64 (21.5)              0.041[c](#jah33226-note-0006){ref-type="fn"}
  Discharge diagnosis                                                                            
  STEMI                                           1236 (52.1)             64 (21.4)              \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Non‐STEMI                                       1138 (47.9)             235 (78.6)             
  Length of hospital stay, d, median (IQR)        3.0 (2.0--5.0)          3.0 (2.0--4.0)         0.010[c](#jah33226-note-0006){ref-type="fn"}
  Severity of disease                                                                            
  Peak troponin, median (IQR)                     7.6 (1.6--29.7)         3.4 (1.1--11.1)        \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Ejection fraction \<40%                         265 (11.5)              29 (9.7)               0.39
  Interventions                                                                                  
  PCI                                             1945 (81.9)             34 (11.4)              \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  CABG                                            248 (10.5)              5 (1.7)                \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  AICD (of patients eligible n=47)                14 (36.8)               4 (44.4)               0.72
  Discharge management (of eligible patients)                                                    
  Aspirin                                         2314 (98.6)             266 (93.7)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Beta blockers                                   2222 (98.3)             213 (85.9)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  ACEI or ARB                                     1573 (73.3)             134 (50.2)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Statin                                          2255 (96.9)             202 (73.4)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Cardiac rehabilitation                                                                         
  Referred on discharge                           1151 (48.5)             97 (32.4)              \<0.001[a](#jah33226-note-0004){ref-type="fn"}
  Reported referral at 1‐mo after AMI follow‐up   1410 (65.1)             127 (46.5)             \<0.001[a](#jah33226-note-0004){ref-type="fn"}

Data are shown as n (%), except as noted. ACEI indicates angiotensin‐converting enzyme inhibitor; AICD, automatic implantable cardioverter‐defibrillator; AMI, acute myocardial infarction; ARB, angiotensin receptor II blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; IQR, interquartile range; MI‐CAD, myocardial infarction due to coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries; OCP, oral contraceptives; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction; TIA, transient ischemic attack.

*P*\<0.001.

*P*\<0.01.

*P*\<0.05.

One‐ and 12‐month post‐AMI outcomes including data on mortality and functional and psychosocial outcomes were collected through follow‐up interviews with the patients. Mortality data were collected through telephone follow‐up, review of medical records at the primary site, and online searches.

MINOCA Versus MI‐CAD Classification {#jah33226-sec-0013}
-----------------------------------

We used the previously published VIRGO taxonomy that classified patients into 5 phenotypes.[18](#jah33226-bib-0018){ref-type="ref"} Briefly, class I included patients with plaque‐mediated obstructive culprit lesions who underwent revascularization; class II included patients with obstructive coronary artery disease (≥50%) but without evident plaque rupture/thrombosis; class III included patients with nonobstructive coronary artery disease (\<50%); class IV included patients with a nonplaque mechanism identified for ischemia by the primary treatment team, including coronary artery vasospasm (relieved by intracoronary nitroglycerin), SCAD (regardless of degree of stenosis), and coronary artery embolization; and class V included patients with undetermined classification. Using this taxonomy, we defined patients for our analysis as follows: Patients were considered to have MI‐CAD if classified as class I or II. Patients in class III or IV were described as having MINOCA.

Statistical Analyses {#jah33226-sec-0014}
--------------------

Descriptive statistics were calculated using counts and percentages for categorical variables and median and interquartile range for continuous variables. To assess statistical significance, χ^2^ and Fisher exact tests were used for categorical variables, and Wilcoxon rank sum tests were used for continuous variables. Symptoms were categorized as *chest pain, other* (non--chest pain symptoms) or *none*. Other variables were defined as follows: current smoking (within the past 30 days), obesity (body mass index ≥30; kg/m^2^), and depression (PHQ‐9 score ≥10). Least squares means and SEs from linear covariance pattern models were used to describe scores on the PSS and the SAQ at baseline and at 1 and 12 months after discharge.[30](#jah33226-bib-0030){ref-type="ref"} Models were selected a priori and included fixed main effects for time, MINOCA status (MINOCA versus MI‐CAD), or sex (men versus women) and the interaction of MINOCA or sex with time. An unstructured covariance pattern was assumed to account for correlation of repeated measures. Adverse health status was defined with SAQ scores as follows: physical limitation \<75, angina frequency \<100, and treatment satisfaction \<75. Overall quality of life from the SAQ was compared for MINOCA and MI‐CAD at 12 months using linear contrasts within the covariance pattern model framework. For modeling functional outcomes, we focused on quality of life because it was significantly different between the 2 groups and served as a summary measure to reflect the influence of disease on a patient\'s perception, symptoms, and function. The influence of differential baseline characteristics between comparison groups was evaluated by sequentially adding covariates to the model and examining their influence on the estimated difference. Eight models were evaluated, sequentially adding groups of demographic, socioeconomic, cardiac risk, other cardiac illness, noncardiac illness, and measures of symptom severity to the model, selected a priori based on their association with quality of life. Differences in quality of life at 12 months are presented with 95% confidence intervals (CIs). A 2‐sided *P*\<0.05 was considered statistically significant. All analyses were performed in SAS version 9.4 (SAS Institute).

Results {#jah33226-sec-0015}
=======

Clinical Characteristics {#jah33226-sec-0016}
------------------------

Figure [S1](#jah33226-sup-0001){ref-type="supplementary-material"} describes patient flow through the VIRGO study. Overall, 47% of eligible patients were not enrolled, and 47 (1%) were adjudicated as noncoronary AMI and did not complete enrollment. These patients were similar to enrolled patients, with a median age of 49 years (interquartile range: 44--52 years), 61% female, and 70% white. Reasons for not enrolling were as follows: 29% were discharged before being contacted by study coordinator, 50% refused consent, \<1% were Spanish speaking and no translator was available, and 21% had other reasons.

Of the 2985 enrolled patients, 295 either did not have an angiogram or received thrombolytics before an angiogram, leaving 2690 participants for analysis. Of those, 2374 (88.4%) were classified as having MI‐CAD, 299 (11.1%) were classified as having MINOCA, and 17 (0.6%) remained unclassified. Using the VIRGO taxonomy, 75 (25.1%) of the MINOCA patients demonstrated a clear mechanism (class IV) with coronary artery vasospasm (n=11), SCAD (n=61), or coronary artery embolization (n=3), whereas the majority (n=224 from class III) had no cause attributed.

Table [1](#jah33226-tbl-0001){ref-type="table"} depicts the overall characteristics and risk factor profiles of patients with MI‐CAD and MINOCA. MINOCA was associated with young age (median: 46 years) and 1.6 times greater likelihood of presenting as non‐STEMI than patients with MI‐CAD (78.6.1% versus 47.9%; *P*\<0.001). Although prevalent overall, fewer MINOCA patients (91.3%) had ≥1 of the traditional cardiac risk factors than MI‐CAD patients (98.7%; *P*\<0.001). Hypercoaguable states were uncommon but seen more frequently with MINOCA than MI‐CAD patients (3.0% versus 1.3%; *P*=0.036). Factors such as autoimmune conditions, psychosocial factors, or use of illicit drugs including cocaine did not differ by AMI type. Women with MI‐CAD were more likely to be menopausal at the time of AMI and to have a history of early menarche than MINOCA patients. They were also more likely to have history of gestational diabetes mellitus, but there were no differences in history of preeclampsia, stillbirth, or miscarriage. Chest pain was the most common presenting complaint for patients with MI‐CAD and MINOCA (87.3% versus 86.3%; *P*=0.63). This was true for both women and men with MINOCA (87.0% versus 80.0%) and with MI‐CAD (86.2% versus 89.3%).

Women had 5 times higher odds of presenting with MINOCA than men (14.9% versus 3.5%; unadjusted odds ratio: 4.84; 95% CI, 3.29--7.13). Nonwhite patients had 1.5 higher odds of having MINOCA than white patients (14.9% versus 10.0%; unadjusted odds ratio: 1.57; 95% CI, 1.21--2.04). With almost 90% of the MINOCA sample being women, further sex‐specific comparisons were limited (Table [S1](#jah33226-sup-0001){ref-type="supplementary-material"}). Women and men appeared to be similar in age, cardiac risk profile, and severity of disease, but women received fewer cardioprotective medications.

Outcomes {#jah33226-sec-0017}
--------

At 1 month, a total of 10 participants were missing (9 with MI‐CAD \[9/2374=0.003\] and 1 with MINOCA \[1/299=0.003\]). At 12 months, a total of 58 were missing (51 with MI‐CAD \[51/2374=0.02\] and 7 with MINOCA \[7/299=0.02\]). Mortality was low for both MINOCA and MI‐CAD patients. Four patients with MI‐CAD and none with MINOCA died during the index hospitalization. The 1‐month mortality for patients with MINOCA was 1.1% compared with 0.6% in MI‐CAD patients (*P*=0.43), whereas 12‐month mortality was 0.6% and 2.3%, respectively (*P*=0.68). Functional and psychosocial outcomes showed a parallel trend in patients with MI‐CAD and MINOCA at baseline, 1 month, and 12 months (Figure [1](#jah33226-fig-0001){ref-type="fig"}). Adverse health status was similar between MINOCA and MI‐CAD at 12 months (7% versus 10%, respectively, for physical limitation \[*P*=0.11\]; 26% versus 31%, respectively, for angina frequency \[*P*=0.17\]; 28% versus 34%, respectively, for quality of life \[*P*=0.07\]), except for treatment satisfaction (15% versus 10%, respectively; *P*=0.03). Unadjusted quality of life for MI‐CAD patients at 12 months was lower compared with MINOCA patients (Table [S2](#jah33226-sup-0001){ref-type="supplementary-material"}). When adjusted for sociodemographic, socioeconomic, clinical, and psychosocial factors, this was no longer true (76.5 versus 73.5 for MINOCA and MI‐CAD, respectively \[*P*=0.06\]; difference between means: 3.08; 95% CI, −0.11 to 6.27).

![Comparison of young patients with myocardial infarction due to coronary artery disease (MI‐CAD) and myocardial infarction with nonobstructive coronary arteries (MINOCA) at baseline, 1 month, and 12 months for (A) mortality; psychosocial outcomes, including (B) depression and (C) perceived stress; and health status, including (D) physical limitations, (E) angina frequency, (F) treatment satisfaction, and (G) quality of life. PHQ‐9 indicates Patient Health Questionnaire; SAQ, Seattle Angina Questionnaire.](JAH3-7-e009174-g001){#jah33226-fig-0001}

A total of 8 women with MINOCA died (1 with vasospasm, 2 with SCAD, and 5 with undefined MINOCA; Figure [2](#jah33226-fig-0002){ref-type="fig"}). No men with MINOCA died within the study period. Women reported lower functional status than men at baseline and at 1 month after AMI. Perceived stress was higher in women than men at baseline and at 12 months (mean score: 21.5 versus 17.3; *P*=0.03); however, these differences were no longer statistically significant at 1 month (mean score: 22.9 versus 20.3; *P*=0.09) or 12 months (mean score: 21.1 versus 18.7; *P*=0.20), after adjusting for baseline scores.

![Comparison of young men and women with myocardial infarction with nonobstructive coronary arteries at baseline, 1 month, and 12 months for (A) mortality; psychosocial outcomes, including (B) depression and (C) perceived stress; and health status, including (D) physical limitations, (E) angina frequency, (F) treatment satisfaction, and (G) quality of life. PHQ‐9 indicates Patient Health Questionnaire; SAQ, Seattle Angina Questionnaire.](JAH3-7-e009174-g002){#jah33226-fig-0002}

Description of MINOCA Phenotypes {#jah33226-sec-0018}
--------------------------------

Overall, 4 patients with MINOCA presented in cardiac arrest and underwent automatic implantable cardioverter‐defibrillator placement. One had a history of familial thrombophilia, 1 had congenital long QTc syndrome, and 1 had coronary microvascular embolization. Despite fewer traditional risk factors, 37 MINOCA patients reported prior AMI (Table [1](#jah33226-tbl-0001){ref-type="table"}), listed as either non‐obstructive CAD (NOCAD) NOCAD or vasospasm on prior angiograms. Thirteen MINOCA patients had a history of heart failure, a third due to preserved ejection fraction. Those with low ejection fraction were older (median age: 50 years) and had a higher proportion of cardiac risk factors than patients with normal ejection fraction (Table [S3](#jah33226-sup-0001){ref-type="supplementary-material"}).

Table [2](#jah33226-tbl-0002){ref-type="table"} demonstrates interesting trends by MINOCA subtype. Patients with undefined MINOCA (class III) had lower peak troponin values than MI‐CAD patients but similar rates of reduced left ventricular function, automatic implantable cardioverter‐defibrillator placement, and length of hospital stay. Yet these patients were significantly less likely to receive secondary prevention medications and cardiac rehabilitation at discharge.

###### 

Clinical Characteristics and Outcomes in Patients With MI‐CAD Versus MINOCA (Undefined, Coronary Artery Vasospasm, Spontaneous Coronary Artery Dissection, or Coronary Artery Embolization)

                                                MI‐CAD (n=2374)     MINOCA Undefined (n=224)   MINOCA Spasm (n=11)   MINOCA Dissection (n=61)   MINOCA Embolization (n=3)
  --------------------------------------------- ------------------- -------------------------- --------------------- -------------------------- ---------------------------
  Demographics                                                                                                                                  
  Age, y, median (IQR)                          48.0 (44.0--52.0)   47.0 (41.0--51.0)          45.0 (37.0--50.0)     44.0 (40.0--51.0)          47.0 (31.0--54.0)
  Women                                         1541 (64.91)        201 (89.73)                10 (90.91)            56 (91.80)                 2 (66.67)
  Race                                                                                                                                          
  Black                                         412 (17.35)         59 (26.34)                 3 (27.27)             6 (9.84)                   1 (33.33)
  White                                         1824 (76.83)        147 (65.63)                7 (63.64)             47 (77.05)                 2 (66.67)
  American Indian                               32 (1.35)           6 (2.68)                   1 (9.09)              1 (1.64)                   0 (0.00)
  Asian/Pacific Islander                        55 (2.32)           4 (1.79)                   0 (0.00)              3 (4.92)                   0 (0.00)
  Other                                         47 (1.98)           8 (3.57)                   0 (0.00)              4 (6.56)                   0 (0.00)
  Hispanic ethnicity                            169 (7.12)          23 (10.27)                 0 (0.00)              8 (13.11)                  0 (0.00)
  Risk factors---conventional                                                                                                                   
  Hypertension                                  1595 (67.19)        134 (59.82)                7 (63.64)             22 (36.07)                 1 (33.33)
  Diabetes mellitus                             750 (31.59)         46 (20.54)                 2 (18.18)             4 (6.56)                   0 (0.00)
  Dyslipidemia                                  1653 (69.63)        122 (54.46)                6 (54.55)             34 (55.74)                 2 (66.67)
  Smoking                                       1430 (60.26)        85 (37.95)                 4 (36.36)             13 (21.31)                 1 (33.33)
  Obesity                                       1285 (54.13)        106 (47.32)                1 (9.09)              17 (27.87)                 2 (66.67)
  Family history of CAD                         1785 (75.25)        142 (63.39)                8 (72.73)             32 (52.46)                 2 (66.67)
  Any of above risk factor                      2342 (98.65)        210 (93.75)                10 (90.91)            50 (81.97)                 3 (100.00)
  Stroke/TIA                                    112 (4.72)          8 (3.57)                   1 (9.09)              0 (0.00)                   0 (0.00)
  Prior AMI                                     517 (21.78)         26 (11.61)                 1 (9.09)              10 (16.39)                 0 (0.00)
  CHF                                           107 (4.51)          11 (4.91)                  1 (9.09)              0 (0.00)                   1 (33.33)
  Prior angina                                  645 (27.20)         44 (19.73)                 6 (54.55)             13 (21.31)                 0 (0.00)
  Known renal dysfunction                       261 (11.05)         24 (10.76)                 2 (18.18)             1 (1.64)                   0 (0.00)
  Known PAD                                     63 (2.66)           0 (0.00)                   0 (0.00)              0 (0.00)                   0 (0.00)
  Risk factors---unconventional                                                                                                                 
  Prior cocaine use                             110 (4.65)          17 (7.59)                  1 (9.09)              0 (0.00)                   0 (0.00)
  Prior other illicit drug use                  192 (8.13)          28 (12.56)                 3 (27.27)             0 (0.00)                   0 (0.00)
  Hypercoagulability syndrome                   31 (1.31)           7 (3.13)                   0 (0.00)              1 (1.64)                   1 (33.33)
  Venous thromboembolism                        62 (2.62)           8 (3.57)                   1 (9.09)              2 (3.28)                   0 (0.00)
  Autoimmune disorder                           70 (2.95)           9 (4.04)                   1 (9.09)              2 (3.28)                   0 (0.00)
  Thyroid disorders                             159 (6.71)          23 (10.27)                 1 (9.09)              5 (8.20)                   0 (0.00)
  For women only (n=1808)                                                                                                                       
  Polycystic ovarian syndrome                   11 (0.72)           1 (0.50)                   0 (0.00)              1 (1.79)                   0 (0.00)
  Menopause                                     850 (55.19)         88 (43.78)                 6 (60.00)             16 (28.57)                 0 (0.00)
  Age at menarche (IQR)                         12.0 (11.0--13.0)   13.0 (11.0--14.0)          15.0 (13.0--16.0)     13.0 (12.0--14.0)          9.5 (8.0--11.0)
  OCP use (n=1395)                              39 (3.27)           7 (4.61)                   0 (0.00)              0 (0.00)                   0 (0.00)
  Ever got pregnant                             1361 (88.38)        177 (88.06)                8 (80.00)             45 (80.36)                 2 (100.00)
  For women who have been pregnant (n=1592)                                                                                                     
  Preeclampsia                                  360 (26.73)         54 (30.86)                 3 (37.50)             9 (20.00)                  1 (50.00)
  Gestational diabetes mellitus                 224 (16.78)         18 (10.29)                 2 (28.57)             5 (11.36)                  0 (0.00)
  Still birth                                   68 (5.04)           9 (5.11)                   0 (0.00)              3 (6.67)                   0 (0.00)
  Miscarriage                                   391 (29.01)         50 (28.41)                 4 (50.00)             10 (22.22)                 1 (50.00)
  Discharge diagnosis                                                                                                                           
  Non‐STEMI                                     1138 (47.94)        193 (86.16)                10 (90.91)            30 (49.18)                 2 (66.67)
  STEMI                                         1236 (52.06)        31 (13.84)                 1 (9.09)              31 (50.82)                 1 (33.33)
  Length of stay, median (IQR)                  3.0 (2.0--5.0)      3.0 (2.0--4.0)             3.0 (2.0--5.0)        4.0 (2.0--5.0)             4.0 (3.0--5.0)
  Severity of disease                                                                                                                           
  Peak troponin, median (IQR)                   7.6 (1.6--29.7)     2.3 (0.8--6.7)             1.5 (0.4--21.4)       12.1 (5.2--35.3)           33.1 (17.7--33.7)
  Ejection fraction \<40%                       265 (11.50)         19 (8.52)                  1 (9.09)              8 (13.11)                  1 (33.33)
  Interventions                                                                                                                                 
  PCI                                           1945 (81.93)        0 (0.00)                   0 (0.00)              34 (55.74)                 0 (0.00)
  CABG                                          248 (10.52)         0 (0.00)                   0 (0.00)              5 (8.20)                   0 (0.00)
  AICD                                          14 (36.84)          4 (44.44)                  0 (0.00)              0 (0.00)                   0 (0.00)
  Discharge management (of eligible patients)                                                                                                   
  Aspirin                                       2314 (98.64)        192 (91.43)                10 (100.00)           61 (100.00)                3 (100.00)
  Beta blocker                                  2222 (98.32)        156 (83.87)                4 (66.67)             50 (94.34)                 3 (100.00)
  ACEI or ARB                                   1573 (73.33)        97 (48.26)                 1 (14.29)             34 (60.71)                 2 (66.67)
  Statins                                       2255 (96.95)        145 (70.39)                5 (62.50)             50 (84.75)                 2 (100.00)
  Cardiac rehabilitation                                                                                                                        
  Referred on discharge                         1151 (48.48)        62 (27.68)                 2 (18.18)             31 (50.82)                 2 (66.67)
  Referred 1 mo after AMI                       1410 (65.10)        79 (39.11)                 2 (20.00)             45 (77.59)                 1 (33.33)
  Outcomes                                                                                                                                      
  Mortality                                                                                                                                     
  In‐hospital mortality                         4 (0.17)            0 (0.00)                   0 (0.00)              0 (0.00)                   0 (0.00)
  1‐mo mortality                                14 (0.59)           2 (0.90)                   0 (0.00)              1 (1.64)                   0 (0.00)
  12‐mo mortality                               53 (2.28)           3 (1.37)                   1 (11.11)             1 (1.64)                   0 (0.00)
  Functional outcomes                                                                                                                           
  SAQ physical limitation score, mean (SD)                                                                                                      
  Baseline                                      80.12 (26.05)       83.32 (24.52)              94.19 (10.28)         88.31 (20.65)              100.00 (0.00)
  1‐mo after AMI                                91.20 (18.77)       90.69 (18.75)              85.28 (25.79)         96.30 (11.48)              100.00 (0.00)
  12‐mo after AMI                               93.00 (17.57)       94.38 (16.42)              84.92 (37.50)         97.82 (8.89)               94.44 (9.62)
  SAQ angina frequency score, mean (SD)                                                                                                         
  Baseline                                      82.69 (20.85)       86.28 (20.14)              89.09 (13.00)         87.87 (15.18)              83.33 (15.28)
  1‐mo after AMI                                88.66 (18.09)       86.90 (18.95)              79.00 (32.81)         91.90 (16.70)              100.00 (0.00)
  12‐mo after AMI                               90.82 (17.45)       92.81 (14.62)              81.43 (30.78)         96.07 (9.08)               83.33 (15.28)
  SAQ treatment satisfaction score, mean (SD)                                                                                                   
  Baseline                                      92.11 (12.47)       89.83 (14.57)              88.07 (12.64)         92.42 (11.86)              100.00 (0.00)
  1‐mo after AMI                                90.62 (14.09)       86.73 (18.36)              81.88 (19.86)         88.04 (12.95)              89.58 (13.01)
  12‐mo after AMI                               91.09 (15.13)       88.23 (19.87)              94.44 (4.87)          89.58 (15.88)              97.92 (3.61)
  SAQ quality of life score, mean (SD)                                                                                                          
  Baseline                                      57.14 (25.15)       60.54 (24.46)              58.33 (15.81)         61.61 (22.38)              69.44 (26.79)
  1‐mo after AMI                                70.12 (25.12)       67.00 (28.85)              61.67 (31.48)         71.84 (20.93)              77.78 (9.62)
  12‐mo after AMI                               73.79 (23.34)       75.65 (22.10)              70.83 (19.54)         80.71 (15.00)              72.22 (9.62)
  Psychosocial outcomes                                                                                                                         
  Depression---PHQ‐9 score \>10                                                                                                                 
  Baseline                                      788 (34.58)         64 (29.63)                 3 (27.27)             15 (25.00)                 1 (33.33)
  1‐mo after AMI                                381 (18.00)         48 (24.24)                 5 (50.00)             6 (10.34)                  0 (0.00)
  12‐mo after AMI                               323 (17.67)         34 (18.89)                 1 (16.67)             6 (11.11)                  0 (0.00)
  Perceived stress, median (IQR)                                                                                                                
  Baseline                                      26.0 (19.0--32.0)   26.0 (20.0--32.5)          30.5 (23.0--35.0)     24.0 (16.0--31.0)          15.0 (13.0--24.0)
  1‐mo after AMI                                21.0 (15.0--28.0)   23.0 (17.0--29.0)          29.0 (18.0--33.0)     20.5 (15.0--25.0)          15.0 (15.0--24.0)
  12‐mo after AMI                               20.0 (14.0--27.0)   21.0 (16.0--27.0)          20.5 (19.0--29.0)     18.0 (13.0--22.0)          23.0 (18.0--26.0)

Data are shown as n (%), except as noted. ACEI indicates angiotensin‐converting enzyme inhibitor; AICD, automatic implantable cardioverter‐defibrillator; AMI, acute myocardial infarction; ARB, angiotensin receptor II blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; IQR, interquartile range; MI‐CAD, myocardial infarction due to coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries; OCP, oral contraceptives; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PHQ‐9, Patient Health Questionnaire; SAQ, Seattle Angina Questionnaire; STEMI, ST‐segment--elevation myocardial infarction; TIA, transient ischemic attack.

In total, 61 patients were diagnosed with SCAD. These patients were younger (median age: 44 years) and often without traditional cardiac risk factors compared with other MINOCA phenotypes (81.9% versus 93.7%); however, they presented often with STEMI (50.8%), had higher troponins, and had more referrals for cardiac rehabilitation than other MINOCA groups (77.6% versus 34.5%; *P*\<0.001). We observed wide variation in revascularization practices for SCAD regardless of degree of stenosis.

Eleven MINOCA patients had vasospasm and 5 times higher odds of having prior angina than other MINOCA patients (odds ratio: 4.80; 95% CI, 1.41--16.28). Triggers identified by the primary treatment team included smoking, sumatriptan, pseudoephedrine, inotropes, hypertension, methamphetamine, and extreme stress. None tested positive for cocaine. None were treated with calcium channel blockers or automatic implantable cardioverter‐defibrillator placement.

Seventeen patients remained unclassified, with prior revascularization but no identifiable cause (Table [S4](#jah33226-sup-0001){ref-type="supplementary-material"}). They were treated similarly to MI‐CAD patients with the exception of referral for cardiac rehabilitation.

Discussion {#jah33226-sec-0019}
==========

We demonstrated that young patients with ischemic MINOCA, representing 11% of our VIRGO population, were more likely to be women, nonwhite, and young; to present with non‐STEMI; and to have fewer traditional risk factors compared with MI‐CAD patients. Outcomes, including mortality and functional and psychosocial status, for patients with MINOCA and MI‐CAD were comparable. The strength and uniqueness of our study lie in the prospectively collected sex‐specific data, such as perinatal and menopausal history, and the detailed psychosocial and health status data that have not been reported previously, comparing MINOCA and MI‐CAD patients. Using a previously validated angiographically based VIRGO taxonomy, we were also able to describe the distinct features of MINOCA phenotypes once the underlying mechanism was defined.[18](#jah33226-bib-0018){ref-type="ref"}

These findings advance our understanding of MINOCA, an area that is rapidly evolving as experts seek consensus on a precise definition.[12](#jah33226-bib-0012){ref-type="ref"} We classified MINOCA as describing patients with coronary‐related ischemia, either in the absence of coronary artery obstruction or from non--plaque‐mediated mechanisms.[13](#jah33226-bib-0013){ref-type="ref"}, [31](#jah33226-bib-0031){ref-type="ref"}, [32](#jah33226-bib-0032){ref-type="ref"}, [33](#jah33226-bib-0033){ref-type="ref"}, [34](#jah33226-bib-0034){ref-type="ref"}, [35](#jah33226-bib-0035){ref-type="ref"} The diverse pathophysiology likely explains the differences in clinical profile, severity, and prognosis that we observed in MINOCA subtypes. We found patients with SCAD, for example, to be younger, more often female, and with few cardiac risk factors but greater severity of disease compared with other MINOCA groups. In contrast, patients with vasospasm more often reported recurrent angina, illicit drug use, and pregnancy‐related complications. With 1 in 10 young patients with AMI diagnosed with MINOCA,[3](#jah33226-bib-0003){ref-type="ref"}, [4](#jah33226-bib-0004){ref-type="ref"}, [5](#jah33226-bib-0005){ref-type="ref"}, [6](#jah33226-bib-0006){ref-type="ref"}, [7](#jah33226-bib-0007){ref-type="ref"}, [8](#jah33226-bib-0008){ref-type="ref"} our findings highlight both the challenges and the importance of pursuing a systematic approach to identify the underlying cause (coronary‐ischemic, non--coronary‐ischemic or nonischemic, or noncardiac).[13](#jah33226-bib-0013){ref-type="ref"}, [36](#jah33226-bib-0036){ref-type="ref"}

Our results also help us better understand the clinical profile of patients with MINOCA. In VIRGO, although these patients had fewer traditional risk factors compared with MI‐CAD patients, they had higher proportions relative to previously studied cohorts of MINOCA or the general population.[5](#jah33226-bib-0005){ref-type="ref"}, [37](#jah33226-bib-0037){ref-type="ref"}, [38](#jah33226-bib-0038){ref-type="ref"}, [39](#jah33226-bib-0039){ref-type="ref"} This could be due to systematic exclusion of patients with presumptive myocarditis and takotsubo, who are often healthier than patients with coronary ischemia such as those enrolled in VIRGO.[37](#jah33226-bib-0037){ref-type="ref"}, [38](#jah33226-bib-0038){ref-type="ref"}, [39](#jah33226-bib-0039){ref-type="ref"} We also noted some interesting nontraditional associations with MINOCA. Hypercoaguable conditions, although infrequent, were more common with MINOCA than MI‐CAD. Prothrombotic states associated with high fibrinogen, factor VII of homocysteine levels, decreased fibrinolytic activity, or deficiency of protein C or S can increase risk of coronary artery embolizations, one of the causes of MINOCA.[40](#jah33226-bib-0040){ref-type="ref"} There was also a sex‐specific association, with women having 4.8 times higher odds of having MINOCA than MI‐CAD in the younger age group (18--55 years). Earlier menarche was more common in MI‐CAD patients, who were also more likely to be obese. High body mass index among adolescents has been linked with early menarche and, later in life, with obesity, insulin resistance, metabolic syndrome, and dyslipidemia, possibly explaining this predisposition.[41](#jah33226-bib-0041){ref-type="ref"}, [42](#jah33226-bib-0042){ref-type="ref"} Other sex‐specific factors such as rates of polycystic ovarian syndrome or pregnancy‐related complications did not differ by type of AMI, but were almost 2 to 3 times higher than in the general population.[43](#jah33226-bib-0043){ref-type="ref"}, [44](#jah33226-bib-0044){ref-type="ref"} Endothelial dysfunction and procoagulant states have been implicated in increasing the long‐term risk of AMI in women with pregnancy‐related complications and warrant further investigation.[45](#jah33226-bib-0045){ref-type="ref"}, [46](#jah33226-bib-0046){ref-type="ref"}, [47](#jah33226-bib-0047){ref-type="ref"}

We noted that the course of MINOCA patients was not benign. Similar proportions of patients with MINOCA and MI‐CAD presented in cardiac arrest, had reduced ejection fraction, or presented with heart failure. They also had similar lengths of hospital stay, possibly as a result of further testing of MINOCA patients to enhance management. Prior studies have shown lower mortality with MINOCA (3.2--4.5%) than with MI‐CAD.[3](#jah33226-bib-0003){ref-type="ref"}, [6](#jah33226-bib-0006){ref-type="ref"}, [7](#jah33226-bib-0007){ref-type="ref"}, [9](#jah33226-bib-0009){ref-type="ref"} We observed lower mortality in VIRGO patients.[5](#jah33226-bib-0005){ref-type="ref"}, [48](#jah33226-bib-0048){ref-type="ref"}, [49](#jah33226-bib-0049){ref-type="ref"}, [50](#jah33226-bib-0050){ref-type="ref"} This could be attributed to the young age of the cohort or the survivor bias for enrollment into VIRGO. Importantly, the 12‐month mortality for MINOCA was still 2 times higher than the 0.5% annual mortality rate observed for a 47‐year‐old woman in the United States.[51](#jah33226-bib-0051){ref-type="ref"} In addition, we noted that short‐ and long‐term functional outcomes of MINOCA and MI‐CAD patients were similar.[52](#jah33226-bib-0052){ref-type="ref"} Women with MINOCA showed a trend for worse functional outcomes than men.

Finally, we observed heterogeneity in MINOCA management, exposing a gap that needs attention.[36](#jah33226-bib-0036){ref-type="ref"} We noted variation in the revascularization strategy in SCAD patients regardless of the degree of stenosis and little use of proven therapies such calcium channel blockers in patients with angiographically demonstrable vasospasm.[53](#jah33226-bib-0053){ref-type="ref"} Recent data also suggest beneficial roles for statins and angiotensin‐converting enzyme inhibitors or angiotensin receptor II blockers in improving mortality and rates of recurrent myocardial infarction in patients with MINOCA, but they were underutilized in our study.[49](#jah33226-bib-0049){ref-type="ref"} The benefit of proven MI‐CAD treatments such as antiplatelet agents or reperfusion may not always apply to MINOCA patients, such as those with coronary artery embolization. Consequently, a standard protocol as used for MI‐CAD treatment may not apply uniformly to all MINOCA patients. These variations underscore the need for prospective pathophysiology‐driven studies that test primary and secondary treatments specific to MINOCA subtype.[10](#jah33226-bib-0010){ref-type="ref"}, [54](#jah33226-bib-0054){ref-type="ref"}, [55](#jah33226-bib-0055){ref-type="ref"}, [56](#jah33226-bib-0056){ref-type="ref"}, [57](#jah33226-bib-0057){ref-type="ref"}

Our results should be interpreted in light of some limitations. First, the angiogram data were recorded by the clinician performing the angiogram and not by a centralized laboratory. Not all sites measured fractional flow reserve, which helps establish the clinical significance of 50% to 75% of lesions; therefore, MINOCA may be underestimated in our patients. However, the decision for treatment at each site was based on interpretation by the cardiologist and thus reflects real‐world clinical practice. Second, this study was voluntary as opposed to a registry, and thus not all patients with AMI were included at each site; consequently, there could be survivor bias in the VIRGO study. We also had low numbers of men with MINOCA in VIRGO, limiting sex‐specific comparisons for patients with MINOCA and nonplaque mechanisms. However, to our knowledge, this study remains the largest with prospectively collected data on young patients with AMI. Finally, VIRGO was originally designed to describe young patients with coronary causes of ischemia and, therefore, systematically excluded myocarditis and takotsubo based on the clinical impression of the treating provider. Correspondingly, we restricted the MINOCA patients in our report to describe coronary causes of ischemia only, consistent with a recent description of MINOCA.[12](#jah33226-bib-0012){ref-type="ref"} In addition, the determination of ischemia in the enrolled VIRGO population was based on close clinical scrutiny. This method, while rigorous and reflective of real‐world practice, still carried some limitations because not all patients had magnetic resonance imaging. It is possible that some patients with myocarditis were included in our cohort. We also recognize that the definition of coronary MINOCA is evolving, particularly concerning takotsubo, which some believe is ischemic but that contemporary belief labels as a "catecholamine cardiomyopathy," as opposed to coronary ischemia. In VIRGO, only a few patients underwent formal provocative testing for coronary artery vasospasm or embolization, limiting our ability to fully characterize disease mechanisms in most patients. This might be due to the common belief that provocative testing in patients with AMI could be dangerous, and our data suggest that routine use of provocative testing in AMI patients is not yet standard of care in the United States. We recognize that the evidence in this space is evolving, and this practice might change, especially with new data from Europe suggesting both the safety and utility of provocative testing in AMI patients[58](#jah33226-bib-0058){ref-type="ref"}; as such, the relative proportion of these various phenotypes should be interpreted with caution.

Conclusion {#jah33226-sec-0020}
==========

Presentation with MINOCA in this sample of young adults with AMI was more common in women, in younger patients, and in nonwhite adults; such patients were more likely to present non‐STEMI and to have fewer traditional cardiac risk factors than patients with MI‐CAD. Patients with MINOCA had similar outcomes, including mortality and psychosocial and functional status, to MI‐CAD patients. The clinical profile and management of MINOCA patients varied by sex and phenotype. Further work is needed to better characterize these patients based on the underlying mechanism.
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